Strategic Decisions for Life Sciences Companies

1

• Strategic Decisions for Life Sciences Companies
• January 17, 2008

2
Context for the Panel

• Case Study of a Typical Life Science Company
• Therapeutic vs. Device company
• Encounter Board issues at each stage of its life
  cycle
• Series A Proof of concept, heading into IND
  and Ph I Trials
• Series B Ph I trials data in (safety, some
  window on efficacy)
• Series C/ IPO/MA Ph II trials data in (dosing
  enough to design pivotal)
• Secondary or MA Ph III, Commercialization,
  and Pipeline development
• Key Board Issues at Each Stage
• Company focus and positioning
• Pipeline development and sequencing
• Capital and partnership strategy

3
Format of Panel

• Panelists
• Not afraid to take strong positions
• Not speaking for their firm in this capacity
• Audience
• Invited to participate along the way
• Rules of engagement
• Brief answers, lively dialog
• Follow the rules of improvisation
• Can assign roles to other panelists
• Can assign other panelists positions that they
  must defend
• Moderator can interrupt change the rules at any
  time

4
Introduction to Our Esteemed Panel
5
Who Ya Gonna Call?

• Nina Kjellson, Partner
• - Interwest Partners
• Cindy Butitta, COO CFO
• - Telik, Inc. (NASDAQ TELK)
• Michael Mischke-Reeds, Managing Partner
• - Keelin Reeds Partners
• ------------------------------------------
• Jeff Karan, Senior Partner
• - Proteus Venture Partners

6
Case Study Cell Busters!

• Oncology company
• Artists conception of breast cancer cell

7
Cell Busters Job
8
T-Cell Killing a Cancer Cell